Charles River Laboratories Intl. Inc (NYSE:CRL) Given Average Recommendation of “Buy” by Analysts

Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) have received an average recommendation of “Buy” from the nineteen brokerages that are covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $145.57.

Several brokerages have weighed in on CRL. Svb Leerink began coverage on shares of Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating and a $155.00 price objective for the company. Leerink Swann began coverage on shares of Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating for the company. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “sell” rating to a “hold” rating in a research note on Thursday, May 9th. Evercore ISI reiterated an “outperform” rating and issued a $160.00 price objective on shares of Charles River Laboratories Intl. in a research note on Tuesday, April 30th. Finally, Wolfe Research began coverage on shares of Charles River Laboratories Intl. in a research note on Tuesday, April 2nd. They issued a “market perform” rating for the company.

Shares of CRL stock opened at $141.90 on Friday. The company has a market cap of $6.92 billion, a P/E ratio of 23.53, a price-to-earnings-growth ratio of 1.76 and a beta of 1.05. The company has a quick ratio of 1.39, a current ratio of 1.63 and a debt-to-equity ratio of 1.10. The business’s 50-day moving average is $131.39. Charles River Laboratories Intl. has a 52 week low of $103.00 and a 52 week high of $149.07.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Tuesday, May 7th. The medical research company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.38 by $0.02. Charles River Laboratories Intl. had a net margin of 9.63% and a return on equity of 23.03%. The business had revenue of $604.57 million during the quarter, compared to the consensus estimate of $587.65 million. During the same quarter in the previous year, the firm posted $1.29 EPS. Charles River Laboratories Intl.’s revenue was up 22.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Charles River Laboratories Intl. will post 6.48 earnings per share for the current fiscal year.

In other news, Director George Massaro sold 3,140 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $134.64, for a total value of $422,769.60. Following the completion of the transaction, the director now directly owns 15,344 shares in the company, valued at approximately $2,065,916.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider William D. Barbo sold 4,905 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $125.16, for a total transaction of $613,909.80. Following the completion of the transaction, the insider now owns 25,859 shares of the company’s stock, valued at $3,236,512.44. The disclosure for this sale can be found here. Insiders sold a total of 9,047 shares of company stock valued at $1,168,322 over the last 90 days. Corporate insiders own 1.80% of the company’s stock.

Large investors have recently modified their holdings of the company. Tompkins Financial Corp grew its holdings in shares of Charles River Laboratories Intl. by 63.1% during the 1st quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 77 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Charles River Laboratories Intl. by 0.8% during the 1st quarter. Louisiana State Employees Retirement System now owns 12,900 shares of the medical research company’s stock valued at $1,874,000 after purchasing an additional 100 shares during the last quarter. State Treasurer State of Michigan grew its holdings in shares of Charles River Laboratories Intl. by 0.6% during the 1st quarter. State Treasurer State of Michigan now owns 17,200 shares of the medical research company’s stock valued at $2,498,000 after purchasing an additional 100 shares during the last quarter. Kwmg LLC grew its holdings in shares of Charles River Laboratories Intl. by 32.4% during the 4th quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 105 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in shares of Charles River Laboratories Intl. by 0.3% during the 1st quarter. Arizona State Retirement System now owns 34,629 shares of the medical research company’s stock valued at $5,030,000 after purchasing an additional 109 shares during the last quarter. Institutional investors own 94.37% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Why does the United States have a lingering trade deficit?

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.